Association between HTLV-I Infection and Chronic Lupoid Leishmaniasis

Fakhroozaman Pezeshkpoori, Seyed Abdol Rahim Rezaei, Abbas Shirdel, Mohammad Khajedaluee, Mansoreh Alizadeh, Mohammad Javad Yazdanpanah

1 Cutaneous Leishmaniasis Research Center, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 HTLV-I Foundation, Immunology Department, Mashhad University of Medical Sciences, Mashhad, Iran
3 Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4 Department of Social Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

* Corresponding author: Mohammad Javad Yazdanpanah, Cutaneous Leishmaniasis Research Center, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Tel: +98-511-8012861; Fax: +98-511-8409612; E-mail: yazdanpanahmj@mums.ac.ir

© 2013 mums.ac.ir All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**ABSTRACT**

**Article Info**

**Article type:** Short Communication

**Article history:**
Received: Mar 27, 2012
Accepted: Aug 2, 2012

**Keywords:**
Cutaneous lupoid leishmaniasis
Cutaneous leishmaniasis
Human T cell lymphotropic virus type 1

**Objective(s):** One of the special types of cutaneous leishmaniasis is the Chronic Lupoid Leishmaniasis (CLL), which abnormal immune responses have been implicated in its pathogenesis. On the other hand, HTLV-I infection has been known to exist in some infectious diseases. Human T cell lymphotropic virus type I (HTLV-I) and cutaneous leishmaniasis exists endemically in Mashhad. The objective of this study was to evaluate the frequency of HTLV-I in CLL patients.

**Materials and Methods:** This cross sectional study involved 51 CLL patients admitted to cutaneous leishmaniasis clinics of Ghaem and Imam Reza hospitals in Mashhad, Iran. The blood samples were examined for serology tests by ELISA method.

**Results:** The results of the tests for evaluating the existence of HTLV-I in 51 patients in this research were proved to be negative.

**Conclusion:** According to this pilot study, the frequency of HTLV-I in CLL patients is not higher than normal population.

---

**Introduction**

Leishmaniasis consists of chronic human infections, developed by types of parasites that are intracellular protozoan parasites.(1) Cutaneous leishmaniasis is endemic in different regions of Iran, including Mashhad.(2) CLL is caused by the recurrent papules around the scars of an old leishmaniasis (3). The exact etiology for the existence of such a leishmaniasis is still unknown. CLL is a clinical form of leishmaniasis. Despite the immune response against parasites and a heightened hypersensitive response, the body’s immune system will not be able to remove the parasite completely and a chronic granulomatous response continues to exist for a long time. (4-6) In 2011, the prevalence of HTLV-I in Mashhad was reported to be 2.12%. (7)

Due to the simultaneous spread of these two diseases in Mashhad on the one hand and the evidences of body’s immune system’s role in those diseases on the other hand, and in order to have a better understanding of CLL pathogenesis and HTLV-I infections, we decided to examine the HTLV-I infections in CLL patients.

**Materials and Method**

In this cross-sectional pilot study, conducted in 2010-2011, 51 CLL patients were included in this research at cutaneous leishmaniasis clinics of Ghaem and Imam Reza...
Hospitals in Mashhad, Iran. The project started soon after obtaining the permission from Ethical Committee. The evidence for the existence of CLL in these patients was based on the primary samples of leishmaniasis lesions after one year and a present clinical form of leishmaniasis. In clinical cases, the lesions were the scars of the newly recovered leishmaniasis, along with the recurrent activation of papules or nodules around or on it. The primary diagnosis was mostly done through smear tests. The skin biopsies confirmed the data collected from the early indefinite diagnosis for 8 patients. After giving sufficient information about the objectives of the study to the patients and obtaining formal consent from them, (in the case of the children, the consent was obtained from their parents), the patients’ special questionnaire were filled. The patients’ blood samples were taken to the laboratory and were examined for serology tests by ELISA (Diaquip kit, made in Italy) method. It was expected that in the case of positive results of ELISA test, the patient’s blood test should be further examined by PCR in order to test the RNA viruses and proviral load.

In order to analyze the data, and to consider demographic characteristics, SPSS software version 16 and T-test and Chi-square nonparametric statistical tests were used.

Results
Fifty-one patients were studied. The mean age was 23.7±19.1 years (Min=3 years, Max=70 years). 29 patients (56.9%) were female and 22 of them (43.1) were male. Fifteen patients had more than one lesion. Location of lesions in the majority of cases was on the face. Mean age of the lesions was 2.08 years in females and 4.2 years in males. ELISA tests for HTLV-I antibodies were negative in all cases.

Discussion
Cutaneous leishmaniasis exists endemically in Mashhad. One of the special types of cutaneous leishmaniasis is the chronic lupoid leishmaniasis which may occur generated after infection with leishmania tropica. Chronic course is one of the characteristics of this type of leishmaniasis and its treatment is also difficult.

Moreover, the investigations about the HTLV-I infection and other associated diseases showed more frequent infections such as strongyloides(8), scabies, leprosy and herpes labial. (9,10) HTLV-I might be responsible for creating disharmonies in body’s immune system through insinuating changes. Thus, it can reinforce the possibility of complications originating from the suppression of immune system. (11)

In addition to the above-mentioned issues with the main basis for this study, is the fact that both HTLV-I and CLL exist endemically in Mashhad. In a study carried out in 1999 in Columbia, the coexistence of HTLV-I with cutaneous leishmaniasis (in three groups of severe, chronic and clinical infections) was examined and was subsequently rejected. (12) In the present study, too, serologic examination of HTLV-I by ELISA method was negative in all patients.

In conclusion, it seems that the frequency of HTLV-I in CLL patients is not much higher than in normal cases. It is obvious that focusing on the immune system factors is not enough for investigating the CLL pathogenesis and other factors including parasite related factors, environmental factors such as sunlight, UV rays and also host-related factors such as genetic factors, age etc should be taken into account. So, CLL could be considered as a multifactorial disease. (13)

Acknowledgment
We would like to thank Dr. Khajedaluee M. and Mrs. Valizadeh N. for their cooperation in this research. This article was extracted from the thesis prepared by Dr. Mansoreh Alizadeh. The research council of the Mashhad University of Medical Sciences, Mashhad, Iran is appreciated for financially supporting this study, grant number2432.

References
1. Lupi O. Protozoa and worms. In: Bolognia JI, Jorizzo JL, Rapini RO, Schafer JV, editors. Dermatology. 2th ed. Spain: Mosby Elsevier; 2008. Vol 1.p.263-290.
2. Oumeish OY. Cutaneous leishmaniasis: a historical perspective. Clin Dermatol 1999; 17:249-254.
3. Asilian A, Iraji F, Hedaiti HR, Sdadat AH, Enshaeiha S. Carbon dioxide laser for the treatment of lupoid cutaneous leishmaniasis (LCL): a case series of 24 patients. Dermatol Online J 2006; 12:3.
4. Vega Lopez F, Hay RJ. Parasitic worms and protozoa. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s text book of dermatology 8 th ed.USA: Blackwell Science; 2010. Vol 2.p.371-44.
5. Ajardy S, Alimohammadian MH, Eslami MB, Kemp K, Khazrazi A. Comparison of the immune profile of nonhealing cutaneous Leishmania patients with those with active lesions and those who have recovered from infection. Infect Immun 2000; 68:760-1764.
6. Stefanidou MP, Antoniou M, Koutsoopoulou AV, Neodtou YT, Krasagakis K, Krüger-Krasagakis S, et al. A rare case of leishmaniasis reactivation after HSCT. Int J Dermatol 2009; 48:586-589.
7. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmad S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol 2011; 52:172-176.
8. Nakada K, Yamaguchi K, Furugen S, Nakasone T, Nakasone K, Ohira Y, et al. Monoclonal integration of HTLV-IV proviral DNA in patients with strongyloidiasis. Int J Cancer 1987; 40:145-148.
9. Gonçalves DU, Guedes AC, Proietti AB, Martins ML, Proietti FA, Lambertucci JR, et al. Dermatologic lesions in asymptomatic blood donors seropositive for human T cell lymphotropic virus type-1. Am J Trop Med Hyg 2003; 68:562-565.
10. Lenz ME, Cuzzo-Maya T, Oliveira AI, Andrade-Serpa MJ, Araújo AQ. Dermatological findings of human T lymphotropic virus type-1 (HTLV-I)-associated myelopathy/tropical spastic paraparesis. Clin Infect Dis 2003; 36:507-513.
11. Kuroda Y, Takashima H. Impairment of cell-mediated immune response in HTLV-I associated myelopathy. J Neurol Sci 1990; 100:211-216.

12. Lenis AM, Blank A, Valderrama I, Saravia NG. Relationship between the human T-lymphotropic virus type 1 infection and clinical manifestations of tegumentary leishmaniasis in the Colombian Pacific Coast. Mem Inst Oswaldo Cruz 1999; 94:19-20.

13. Meymandi S, Dabiri S, Shamsh-Meymandi M, Nikpour H, Kharazmi A. Immunophenotypic pattern and cytokine profiles of dry type cutaneous leishmaniasis. Arch Iran Med 2009; 12:371-376.